VAC approval is nice, but how many sales are likely to smaller hospitals with limited staff capacity? Many of these smaller hospitals are likely waiting on Recell Go. Without Go, sales will be much more slow. The August VAC success projection for 2024 predated the FDA delay. Training for each ease of use sale will take up considerable time and expense once Avita tries to spread its wings to said smaller hospitals. Also, Go needed for international expansion and vitiligo. It’s a crapshoot.
Ann: AVITA Medical Q3 Revenue & Secures $90M Non-Dilutive Debt, page-97
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.71 |
Change
-0.250(8.45%) |
Mkt cap ! $168.5M | |||
| Open | High | Low | Value | Volume |
| $2.78 | $2.83 | $2.71 | $2.015M | 728.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3071 | $2.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.73 | 1874 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.72 |
Change
-0.250 ( 8.30 %) |
||||
| Open | High | Low | Volume | ||
| $2.79 | $2.83 | $2.71 | 12865 | ||
| Last updated 15.57pm 09/05/2024 ? | |||||
| AVH (ASX) Chart |